Bexson Biomedical to present at the H.C. Wainwright and Beryl Elites Conferences | News


SANTA BARBARA, Calif., June 17, 2022 /PRNewswire/ — Bexson Biomedical, Inc., a research-phase company establishing therapies and supply answers for pain administration, habit and psychological wellbeing indications, will existing details on its R&D pipeline combining wearable supply gadgets with subcutaneous formulation engineering at two trader activities this thirty day period.

First, co-founder and Main Science Officer, Jeffrey Becker, MD, will acquire the phase at Beryl Consulting Group’s 4th Annual Different Investments & Innovation Meeting to be held in New York Town on June 20th and 21st. Becker will contribute to a panel checking out breakthrough innovations and financial investment alternatives throughout psychedelics and psychiatry.

Then, co-founder and CEO, Gregg Peterson, will give a company update at the H.C. Wainwright 1st Annual Psychological Health and fitness Meeting: Neuropsychiatry, Psychedelics, and Beyond on June 27th, also in New York. Peterson will existing Bexson’s ongoing strategy for the supply of psychedelic therapies for a variety of indications by means of its unique subcutaneous formulation technologies and wearable shipping and delivery platform. Bexson is acquiring a pre-loaded, pre-sterilized pump method in conjunction with Italian drug delivery and clinical device manufacturer, Stevanato Group.

Facilitated by HC Wainwright & Co, one particular of the major expenditure banking companies for the biotech sector, the hybrid celebration is established to element researchers, business leaders and institutional traders in the rising psychedelic area.

For much more details about Beryl Consulting Group’s occasion, go to:

For additional information and facts about the HC Wainwright & Co event, check out:

Bexson Biomedical, Inc. is a investigation stage organization producing therapies for a broad variety of ache administration, addiction and mental well being diseases. The company’s direct sign for its BB106 treatment is acute discomfort management. Article-operative suffering administration is a $12 billion market and a leading result in of opioid abuse and habit. Take a look at at:

Cision Look at initial content to download multimedia:

Resource Bexson Biomedical


Source connection